<DOC>
	<DOC>NCT00709865</DOC>
	<brief_summary>The purpose of the current study is to assess the safety and tolerability of intravenous tonapofylline.</brief_summary>
	<brief_title>Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Previous diagnosis of heart failure. Must have ADHF, requiring hospitalization, with clinical evidence for volume overload History of an allergic reaction to any xanthinecontaining substance. History of seizure History of stroke Myocardial infarction Uncorrected hemodynamically significant primary valvular disease or known Obstructive or restrictive cardiomyopathy. Serious systemic infection Major surgical procedures within 30 days Acute coronary syndrome Cardiogenic shock Baseline body weight &gt;150 kg Participation in any other investigational study of drugs or devices within 30 days prior to Screening Nursing mothers, pregnant women, or women planning on becoming pregnant during the study Presence of any clinically significant condition that might interfere with optimal safe participation in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>renal insufficiency</keyword>
	<keyword>diuretic</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>acute decompensated heart failure</keyword>
</DOC>